Study of the correlation of baseline biomarkers and DNA demethylation to clinical responses in a phase 1 2, randomized study of SGI-110, a novel subcutaneous hypomethylating agent in the treatment of relapsed refractory - Biomarkers - Document - PDFSEARCH.IO

First Page		Document Content
Medicine Epigenetics Biology Acute leukemia Myeloid leukemia Azacitidine Acute myeloid leukemia Hypomethylating agent Decitabine Oncology Nucleosides Triazines		Study of the correlation of baseline biomarkers and DNA demethylation to clinical responses in a phase 1/2, randomized study of SGI-110, a novel subcutaneous hypomethylating agent in the treatment of relapsed/refractory Add to Reading List Source URL: astx.com Download Document from Source Website File Size: 902,59 KB Share Document on Facebook

	The Dual E-selectin/CXCR4 Antagonist GMI-1359 Exerts Anti-leukemia Efficacy Against FLT3-ITDmutated Acute Myeloid Leukemia in A Patient-derived Xenograft Murine Model Mouse-1 Mouse-2 DocID: 1uSbg - View Document
$A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan$	A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan DocID: 1uJQ2 - View Document
	Vascular E-Selectin Mediates Chemo-Resistance in Acute Myeloid Leukemia Initiating Cells Via Canonical Receptors PSGL-1 (CD162) and Hcell (CD44) and AKT Signaling Ingrid G Winkler, PhD1, Johanna M Erbani, PhD student2, DocID: 1u5Xi - View Document
	Microsoft Word - Publikationsliste_Leukämie.doc DocID: 1rn6f - View Document
	Megan Othus 1100 Fairview Avenue North M3-C102 PO BoxSeattle, WAEducation DocID: 1rb02 - View Document